Corrigendum to “Dual-targeting liposomal delivery of sorafenib and docetaxel for enhanced synergistic therapy in advanced hepatocellular carcinoma” [Pharmaceut. Sci. Adv. 2 (2024) 100046]
Pharmaceutical Science Advances · 2026-12 · 4 · 100145
DOI: 10.1016/j.pscia.2026.100145 ↗Kurz gefasst
Korrektur in der Zeitschrift Pharmaceutical Science Advances, 2026-12. Verfasst von Yawen Yao und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutics, School of Pharmacy, China Pharmaceutical University, 24 Tong Jia Xiang, Nanjing, 210009, China. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Autor:innen und Institutionen
- Department of Pharmaceutics, School of Pharmacy, China Pharmaceutical University, 24 Tong Jia Xiang, Nanjing, 210009, China.
- Institute of Chinese Medical Sciences, State Key Laboratory of Quality Research in Chinese Medicine, University of Macau, Macao Special Administrative Region of China, China.
- Center of Pharmacokinetics, Key Laboratory of Drug Metabolism and Pharmacokinetics, China Pharmaceutical University, Nanjing, 210009, China.
Zitieren
APA
Yao, Y., Hu, Y., Meng, X., Feng, F., Xu, F., Wang, G., Yu, H., & Li, J. (2026). Corrigendum to “Dual-targeting liposomal delivery of sorafenib and docetaxel for enhanced synergistic therapy in advanced hepatocellular carcinoma” [Pharmaceut. Sci. Adv. 2 (2024) 100046]. Pharmaceutical Science Advances, 4, 100145. https://doi.org/10.1016/j.pscia.2026.100145
Vancouver
Yao Y, Hu Y, Meng X, Feng F, Xu F, Wang G, et al. Corrigendum to “Dual-targeting liposomal delivery of sorafenib and docetaxel for enhanced synergistic therapy in advanced hepatocellular carcinoma” [Pharmaceut. Sci. Adv. 2 (2024) 100046]. Pharmaceutical Science Advances. 2026;4:100145. doi:10.1016/j.pscia.2026.100145
BibTeX
@article{Yao2026,
author = {Yao, Yawen and Hu, Yue and Meng, Xinwang and Feng, Fenyan and Xu, Feng and Wang, Guangji and Yu, Hua and Li, Juan},
title = {Corrigendum to “Dual-targeting liposomal delivery of sorafenib and docetaxel for enhanced synergistic therapy in advanced hepatocellular carcinoma” [Pharmaceut. Sci. Adv. 2 (2024) 100046]},
journal = {Pharmaceutical Science Advances},
year = {2026},
volume = {4},
pages = {100145},
doi = {10.1016/j.pscia.2026.100145}
}
EUVIMED